Connecticut Attorney General William Tong filed a lawsuit against Triggered Brand for selling unapproved 'research grade' GLP-1 weight loss drugs directly to consumers without prescriptions or medical oversight, violating the Connecticut Unfair Trade Practices Act and pharmacy licensing laws. The AG also issued a Civil Investigative Demand to Made In China for similar sales and sent warning letters to weight loss clinics about compounded GLP-1 drugs.
The lawsuit seeks civil penalties of up to $5,000 per violation for selling unapproved drugs without a pharmacy license and engaging in unfair trade practices.
In-house legal teams should review vendor and supplier agreements to ensure partners hold valid pharmacy licenses, only distribute FDA-approved drugs, mandate prescriptions for prescription medications, and prohibit the sale of 'research-grade' or unapproved compounds for human consumption. Contracts should include compliance with state unfair trade practices laws, robust product safety and labeling requirements, and restrictions on deceptive marketing of compounded or counterfeit medications.
Entity
Triggered Brand
Industry
HealthcareOfficial Press Release
https://portal.ct.gov/ag/press-releases/2025-press-releases/attorney-general-tong-sues-glp-1-weight-loss-drug-distributor-triggered-brand
letter to wt loss clinics spas 52125 final.pdf?rev=092249d64
https://portal.ct.gov/-/media/ag/press_releases/2025/letter-to-wt-loss-clinics--spas-52125-final.pdf?rev=092249d64e7944379af755e39def28d2&hash=691621FFBBCB39EF0AC957F4586F2FC0
Connecticut Attorney General Enforcement Page
https://portal.ct.gov/AG/Privacy/Privacy-Resources
"Triggered Brand"
"Connecticut Unfair Trade Practices Act"
"statutes prohibiting the practice of pharmacy without a license"
"sell 'research grade' GLP-1 peptides direct to Connecticut consumers for weight loss without prescriptions or any medical oversight"
$625K
Connecticut reached a $625,000 settlement with Frontier Communications Parent Inc. over an April 2024 breach in which compromised employee and vendor credentials were used to access internal systems and exfiltrate unencrypted personal information of 58,841 Connecticut residents. The settlement requires Frontier to strengthen its security program, implement specific safeguards and training, and obtain an independent third-party assessment.
$2.6M
Connecticut and New York found that Boston Children’s Health Physicians and its security vendor, XTIUM, failed to use reasonable safeguards, resulting in hackers accessing sensitive personal, medical, and employee information. The companies agreed to pay penalties totaling $2.64 million and implement enhanced cybersecurity measures.
Connecticut joined a coalition of state attorneys general filing a notice in Character Technologies, Inc.’s bankruptcy proceedings, raising concerns about the company’s safety and privacy practices and the sensitive information it holds. The states seek protections for children and consumers if the company’s business or assets are sold or transferred; the filing does not impose a fine or other remedy.
Attorney General William Tong and Consumer Counsel Claire Coleman petitioned PURA to review how Connecticut public utilities use artificial intelligence, citing potential data privacy and cybersecurity risks, algorithmic errors, and misleading outputs. The petition asks PURA to examine utility AI systems, safeguards, vendors, and data security practices; it does not report a finding of violation or an imposed penalty.
$2.0M
Connecticut Attorney General William Tong announced a settlement with RZ Smoke, Inc. over allegations that it distributed and sold high-potency cannabis products without a state license. The stipulated judgment is $2 million, with $375,000 payable to the State and $1.6 million suspended to ensure compliance; the company is barred from specified cannabis activities in Connecticut unless licensed.
$13.7M
Connecticut joined a coalition of states and the federal government in settling allegations that Takeda paid healthcare providers speaker honoraria and provided meals to induce prescriptions of Trintellix, leading to allegedly false claims to government healthcare programs. Takeda agreed to pay $13,670,921 plus accrued interest, with portions allocated to federal and state programs.